$12.19
4.37%
NYSE, Sep 17, 04:00 pm EDT. Closed.
ISIN
US2561352038
Symbol
RDY

Dr. Reddy's Laboratories Ltd. Sponsored ADR Target price 2026 - Analyst rating & recommendation

Dr. Reddy's Laboratories Ltd. Sponsored ADR Classifications & Recommendation

Buy
31%
Hold
24%
Sell
44%

Dr. Reddy's Laboratories Ltd. Sponsored ADR Price Target

Target Price $12.95
Price $12.19
Potential
Number of Estimates 40
40 Analysts have issued a price target Dr. Reddy's Laboratories Ltd. Sponsored ADR 2027 . The average Dr. Reddy's Laboratories Ltd. Sponsored ADR target price is $12.95. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 45 analysts: 14 Analysts recommend Dr. Reddy's Laboratories Ltd. Sponsored ADR to buy, 11 to hold and 20 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Dr. Reddy's Laboratories Ltd. Sponsored ADR stock has an average upside potential 2027 of . Most analysts recommend the Dr. Reddy's Laboratories Ltd. Sponsored ADR stock at Sale.

Sales and Margin forecast 2027, 2028 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Billion $ 3.52 3.71
3.24% 5.91%
EBITDA Margin 20.19% 17.92%
24.37% 11.26%

39 Analysts have issued a sales forecast Dr. Reddy's Laboratories Ltd. Sponsored ADR 2027 . The average Dr. Reddy's Laboratories Ltd. Sponsored ADR sales estimate is

$3.7b
unlock
. This is
7.41% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.0b 16.46%
unlock
, the lowest is
$3.2b 8.37%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 $3.5b 3.24%
2027
$3.7b 5.91%
unlock
2028
$4.1b 11.68%
unlock
2029
$4.6b 10.07%
unlock
2030
$4.7b 3.23%
unlock
2031
$5.0b 7.07%
unlock

40 Analysts have issued an Dr. Reddy's Laboratories Ltd. Sponsored ADR EBITDA forecast 2027. The average Dr. Reddy's Laboratories Ltd. Sponsored ADR EBITDA estimate is

$665m
unlock
. This is
16.46% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$863m 51.02%
unlock
, the lowest is
$547m 4.29%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 $710m 21.92%
2027
$665m 5.99%
unlock
2028
$852m 28.06%
unlock
2029
$971m 13.92%
unlock
2030
$1.2b 20.90%
unlock
2031
$1.3b 11.40%
unlock

EBITDA Margin

2026 20.19% 24.37%
2027
17.92% 11.26%
unlock
2028
20.55% 14.68%
unlock
2029
21.27% 3.50%
unlock
2030
24.92% 17.16%
unlock
2031
25.92% 4.01%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share $ 0.53 0.46
25.35% 11.54%
P/E 25.64
EV/Sales 2.64

41 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast for earnings per share. The average Dr. Reddy's Laboratories Ltd. Sponsored ADR EPS is

$0.46
unlock
. This is
15.00% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
$0.63 57.50%
unlock
, the lowest is
$0.30 25.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 $0.53 25.35%
2027
$0.46 11.54%
unlock
2028
$0.60 30.43%
unlock
2029
$0.71 18.33%
unlock

P/E ratio

Current 29.20 53.37%
2027
25.64 12.19%
unlock
2028
19.37 24.45%
unlock
2029
16.34 15.64%
unlock

Based on analysts' sales estimates for 2027, the Dr. Reddy's Laboratories Ltd. Sponsored ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.84
2027
2.64 7.01%
unlock
2028
2.36 10.45%
unlock
2029
2.15 9.15%
unlock
2030
2.08 3.13%
unlock
2031
1.94 6.60%
unlock

P/S ratio

Current 2.89 11.01%
2027
2.69 6.90%
unlock
2028
2.41 10.46%
unlock
2029
2.19 9.15%
unlock
2030
2.12 3.13%
unlock
2031
1.98 6.60%
unlock

Current Dr. Reddy's Laboratories Ltd. Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HSBC
Locked
Locked
Locked Jun 05 2025
Analyst Rating Date
Locked
HSBC:
Locked
Locked
Jun 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today